Metabolic Effects of Vitamin D in Patients With Type 2 Diabetes (ProjectD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to examine the effect on metabolic parameters after 12 weeks of treatment with high dose vitamin D in patients with type 2 diabetes and vitamin D insufficiency.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 2 Diabetes Vitamin D Insufficiency |
Drug: Cholecalciferol |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | Metabolic Effects of Vitamin D in Patients With Type 2 Diabetes - a Randomized Controlled Trial |
- Insulin secretion and insulin resistance [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
- Glycemic control, lipid status, inflammatory markers, BMD [ Time Frame: 2 months ] [ Designated as safety issue: No ]
| Enrollment: | 16 |
| Study Start Date: | December 2008 |
| Study Completion Date: | June 2010 |
| Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Cholecalciferol |
Drug: Cholecalciferol
8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
|
| Placebo Comparator: Placebo pill |
Drug: Cholecalciferol
8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
|
Detailed Description:
There is increasing evidence that vitamin D affects the risk of diabetes. The role of vitamin D in type 2 diabetes is suggested by cross sectional studies, where an inverse association between vitamin D status and the development of type 2 diabetes has been found. Moreover supplementation with calcium and vitamin D may attenuate increases in glycemia and insulin resistance in healthy older adults with IFG. However further research is needed to confirm these findings and to determine possible mechanisms of the preventive effect from vitamin D against diabetes. The aim of this study is to examine the effect on metabolic parameters such as glycemic control, lipid status, inflammatory markers, insulin resistance and insulin secretion in patients with type 2 diabetes and vitamin D insufficiency before and after a 12-week period of treatment with high doses of vitamin D.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Informed consent
- Type 2 diabetes
- Patients of Danish extraction
- Vitamin D insufficiency (1,25OHvitD < 50 nmol/l)
Exclusion Criteria:
- Nephropathy (Urea > 12 mmol/l)
- S-calcium > 2,52 mmol/L
- Primary hyperparathyroidism
- Serious disease
- Malabsorption
- Sarcoidosis
- Pregnancy
Contacts and Locations| Denmark | |
| Medical Research Unit, Medical Department M, Aarhus University Hospital | |
| Aarhus, Denmark, 8000 | |
| Principal Investigator: | Lotte Oeskov, MD | Medical Department, Silkeborg Hospital, Falkevej 1-3, 8600 Silkeborg, Denmark |
More Information
No publications provided
| Responsible Party: | MD, Med. Sci. Lotte Oerskov, Medical Department, Silkeborg Hospital |
| ClinicalTrials.gov Identifier: | NCT00812578 History of Changes |
| Other Study ID Numbers: | UKO-1006-2008 |
| Study First Received: | December 19, 2008 |
| Last Updated: | July 9, 2010 |
| Health Authority: | Denmark: Danish Dataprotection Agency Denmark: Danish Medicines Agency Denmark: The Regional Committee on Biomedical Research Ethics |
Keywords provided by University of Aarhus:
|
Type 2 diabetes Vitamin D insufficiency Insulin secretion Insulin sensitivity Pulsatility |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Cholecalciferol Vitamin D |
Ergocalciferols Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on May 19, 2013